ARAV
Closed
Aravive Inc
0.0401
-0.0062 (-13.39%)
Last Update: 07 Feb 2024 17:30:00
Yesterday: 0.0463
Day's Range: 0.0401 - 0.0401
Send
sign up or login to leave a comment!
When Written:
2
Aravive Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for the treatment of cancer and fibrosis. The company's lead product candidate, AVB-S6-500, is a novel, high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway, which is implicated in the growth and spread of multiple types of cancer. Aravive is also developing AVB-500, a first-in-class, ultra-high-affinity decoy protein that targets the GAS6-AXL signaling pathway, for the treatment of fibrosis and other diseases. The company is headquartered in Houston, Texas, and was founded in 2007.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








